{
  "docId": "019de075-8d44-7401-b489-ee436db9a207",
  "docSlug": "66ec60e76d61a423395d466c32dc56fb",
  "documentTitle": "Exscientia | Investor Presentation Deck | 75 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 75,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a human anatomy diagram to map patient counts to specific disease locations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8d44-7401-b489-ee436db9a207/31",
  "deckHref": "/decks/019de075-8d44-7401-b489-ee436db9a207",
  "deckJsonHref": "/decks/019de075-8d44-7401-b489-ee436db9a207.json",
  "deckAnchorHref": "/decks/019de075-8d44-7401-b489-ee436db9a207#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.68,
        "y": 0.58
      },
      "kind": "callout",
      "text": "Biomarker work ongoing",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc5f24d2-cf0e-4a84-82ef-6f0459280e89",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.35,
        "x": 0.25,
        "y": 0.18
      },
      "kind": "image",
      "text": "Human anatomy diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c0a6c98-e665-41b3-9fca-756cc4a906c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.68,
        "y": 0.46
      },
      "kind": "metric",
      "text": "~34K",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0cea39dc-c27b-433e-a6aa-9eaaf8b457a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.05,
        "x": 0.07,
        "y": 0.41
      },
      "kind": "metric",
      "text": "29K",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e64503b-69a6-4627-9e54-131e03eeede8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.05,
        "x": 0.48,
        "y": 0.41
      },
      "kind": "metric",
      "text": "5K",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "635da647-184d-4e3b-9572-d4bba97d9008",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.07,
        "y": 0.47
      },
      "kind": "paragraph",
      "text": "Non-small Cell Lung Cancer 2nd or later line of therapy, without driver mutations*",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0303511d-8605-4548-b427-f2ff40aaace3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.85,
        "y": 0.48
      },
      "kind": "paragraph",
      "text": "U.S. Patients Lives Annually",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "891ee2e0-f7f4-4235-b0fa-1562da68003a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.48,
        "y": 0.47
      },
      "kind": "paragraph",
      "text": "Renal Cell Carcinoma Cancer 2nd or later line of therapy, post-IO",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95565539-dad7-49f3-8623-db39a42cf3dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.09
      },
      "kind": "source-note",
      "text": "Covers all indications included in Ph 1/2 IGNITE trial in U.S.; Patient counts for each subtype based on EvaluatePharma Epidemiology 2022 and primary inclusion criteria for IGNITE Ph 1/2 trial. Globocan used for incidence within each subtype. Treatment rate and progression rates based on Cerner Enviza Treatment Architecture Reports 2022 – U.S. reported assumptions used for global numbers. Numbers have been rounded to the nearest 1000, patient per year. *Excludes currently actionable driver mutations such as ALK, EGFR, BRAF, ROS1, RET and MET",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5530870c-18d4-4fae-8c85-41d87c0b43d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "2022 United States incidence for patient sub-groups included in IGNITE trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0abd5e5b-65e7-4c81-bd43-c921ee8ad624",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "IGNITE: '546 Phase 1/2 initiated in RCC & NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c28d63e1-28ff-48e2-a1f2-4dc05ceb5d9b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 31,
      "from": 30,
      "beatId": "2d0aeaeb-f8d0-4500-8e7c-7adbf7e68677",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Visualization",
      "beatSlug": "monroes-sequence-visualization",
      "evidence": "IGNITE: '546 Phase 1/2 initiated in RCC & NSCLC",
      "position": 5,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}